Management of venous thromboembolism in patients with acute leukemia at high bleeding risk: a multi-center study

6533b83afe1ef96bd12a6f14

RESEARCH PRODUCT

Management of venous thromboembolism in patients with acute leukemia at high bleeding risk: a multi-center study

Francesco Fabbiano Mariasanta Napolitano Sergio Siragusa Calogero Vetro Maria Ilaria Del Principe Alessandro Lucchesi Giorgia Saccullo Casuccio Alessandra Luca Valore Maria Enza Mitra Anna Candoni Alessandra Malato Donato Mannina Francesco Di Raimondo

subject

Adult Male Cancer Research medicine.medical_specialty medicine.drug_class medicine.medical_treatment Population Low molecular weight heparin Hemorrhage 030204 cardiovascular system & hematology Young Adult 03 medical and health sciences 0302 clinical medicine Venous thrombosis Low Molecular Weight Heparin Humans Medicine acute leukemia cardiovascular diseases education Aged Aged 80 and over Venous Thrombosis Acute leukemia education.field_of_study Acute leukemia Chemotherapy Leukemia business.industry low molecular weight heparin Incidence Incidence (epidemiology)Disease Management Venous Thromboembolism Hematology Middle Aged medicine.disease Pulmonary embolism Surgery Venous thrombosis Oncology 030220 oncology & carcinogenesis Acute Disease Female acute leukemia; low molecular weight heparin; Venous thrombosis business Settore MED/15 - Malattie del Sangue Venous thromboembolism

description

In the last decades, evaluation of clinically relevant thrombotic complications in patients with acute leukemia (AL) has been poorly investigated. The authors performed a multi-center study to evaluate the management of symptomatic venous thromboembolism (VTE) in adult patients with AL. The intention was to find as clinically relevant the following: symptomatic Venous Thrombosis (VT) occurred in typical (lower limbs) and atypical (cerebral, upper limbs, abdominal, etc) sites with or without pulmonary embolism (PE). Over a population of 1461 patients with AL, 22 cases of symptomatic VTE were recorded in hospitalized patients with a mean age of 54.6 years. The absolute incidence of VTE was 1.5%. VTE occurred during chemotherapy in 17/22 (77.2%) cases, mainly (14/17, 82.3%) during the induction phase. Treatment of acute VTE was based on Low Molecular Weight Heparin (LMWH) at full dosage for the first month from diagnosis and reduced dosage (75%) for the following months.

year	journal	country	edition	language
2016-01-01	Leukemia & Lymphoma

https://doi.org/10.3109/10428194.2015.1046864